Loading
Loading
Growth Hormone & Secretagogues · 10mg
Janoshik-tested · 10 vials per kit
Ipamorelin is a selective growth hormone secretagogue pentapeptide studied in preclinical research for its GH-releasing properties. Research has examined its potential to selectively stimulate GH secretion via ghrelin receptors without significantly affecting cortisol, prolactin, or ACTH levels. Studies have explored applications in GH deficiency, bone density, lean muscle support, and fat metabolism models.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Ipamorelin
Ipamorelin is a synthetic pentapeptide ghrelin mimetic and selective GH secretagogue receptor (GHS-R1a) agonist. Developed in the 1990s, it is considered highly selective for GH release with minimal effects on cortisol, prolactin, or ACTH at therapeutic doses — an advantage over earlier GH secretagogues (GHRP-2, GHRP-6) which stimulate cortisol and prolactin more substantially.
Ipamorelin acts as an agonist at ghrelin receptors (GHS-R1a) on somatotroph cells of the anterior pituitary, stimulating GH release in a dose-dependent fashion. The GH pulse produced is amplified by concurrent GHRH signalling — which is why Ipamorelin is frequently studied in combination with CJC-1295 DAC, Tesamorelin, or Sermorelin. GHS-R1a and GHRH receptors activate complementary intracellular pathways (IP3/PKC and cAMP/PKA respectively), producing synergistic GH pulses exceeding either agent alone.
Research has examined Ipamorelin for GH-axis support, body composition (lean mass preservation with visceral fat reduction), bone mineral density support, cardiac function (GH has direct cardiac receptor activity), and recovery from catabolic states. Combination GHRP + GHRH protocols using Ipamorelin plus a GHRH analog are among the most commonly studied GH-stimulation strategies in preclinical research.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
